^
    Apply
    Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer (NCT05573126)
    Phase 1/2
    Ellipses Pharma
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/11/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2026
    HER-2
    |
    HER-2 negative
    |
    everolimus • Orserdu (elacestrant) • vosilasarm (EP0062)
    A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (SUMIT-ELA) (NCT05963997)
    Phase 1/2
    Carrick Therapeutics Limited
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/09/2023
    Primary completion :
    12/23/2025
    Completion :
    12/23/2025
    HER-2 • ER • TP53 • CDK4
    |
    TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation
    |
    Orserdu (elacestrant) • samuraciclib (CT7001)
    Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE) (NCT05563220)
    Phase 1/2
    Stemline Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/24/2023
    Primary completion :
    12/27/2026
    Completion :
    12/28/2028
    HER-2 • ER • PIK3CA • CDK4
    |
    PIK3CA mutation
    |
    Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • Orserdu (elacestrant)
    Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer (ELECTRA) (NCT05386108)
    Phase 1/2
    Stemline Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/31/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • Orserdu (elacestrant)
    ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study (ELCIN) (NCT05596409)
    Phase 2
    Stemline Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    05/19/2023
    Primary completion :
    02/01/2025
    Completion :
    08/01/2025
    HER-2 • ER
    |
    Orserdu (elacestrant)
    Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA) (NCT06382948)
    Phase 3
    MedSIR
    Not yet recruiting
    Last update posted :
    04/26/2024
    Initiation :
    06/01/2024
    Primary completion :
    09/01/2027
    Completion :
    04/01/2028
    HER-2 • ER • CDK4
    |
    HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation
    |
    everolimus • Orserdu (elacestrant)
    Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) (NCT03778931)
    Phase 3
    Stemline Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/10/2019
    Primary completion :
    08/24/2021
    Completion :
    08/01/2024
    HER-2 • ER
    |
    fulvestrant • letrozole • anastrozole • exemestane • Orserdu (elacestrant)
    DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (NCT06075953)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    02/14/2024
    Primary completion :
    11/01/2028
    Completion :
    11/01/2033
    HER-2
    |
    HR positive
    |
    tamoxifen • letrozole • anastrozole • exemestane • Orserdu (elacestrant)
    Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104) (NCT05982093)
    Phase 2
    SOLTI Breast Cancer Research Group
    Recruiting
    Last update posted :
    02/13/2024
    Initiation :
    10/03/2023
    Primary completion :
    10/01/2024
    Completion :
    01/01/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • HER-2 expression
    |
    Orserdu (elacestrant) • triptorelin
    Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (NCT05512364)
    Phase 3
    European Organisation for Research and Treatmen...
    Recruiting
    Last update posted :
    01/24/2024
    Initiation :
    12/15/2023
    Primary completion :
    07/01/2028
    Completion :
    05/01/2030
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    tamoxifen • letrozole • anastrozole • exemestane • Orserdu (elacestrant)
    Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT) (NCT06201234)
    Phase 2
    German Breast Group
    Not yet recruiting
    Last update posted :
    01/11/2024
    Initiation :
    03/31/2024
    Primary completion :
    03/31/2028
    Completion :
    03/31/2028
    HER-2 • BRCA1
    |
    HER-2 negative • PALB2 mutation • PTEN mutation + HR positive
    |
    Zejula (niraparib) • Orserdu (elacestrant)
    Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer (NCT06062498)
    Phase 2
    Northwestern University
    Not yet recruiting
    Last update posted :
    10/02/2023
    Initiation :
    09/30/2023
    Primary completion :
    07/01/2024
    Completion :
    07/01/2025
    HER-2 • ER
    |
    ER positive • HER-2 negative • ER mutation • ESR1 mutation
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Orserdu (elacestrant)
    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (NCT05826964)
    Phase 2
    University of Miami
    Recruiting
    Last update posted :
    08/21/2023
    Initiation :
    06/12/2023
    Primary completion :
    07/31/2026
    Completion :
    07/31/2029
    HER-2 • ER
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • everolimus • tamoxifen • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • Orserdu (elacestrant) • Navelbine oral (vinorelbine tartrate oral)
    Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer (Lilly-I3Y-US-I026) (NCT04791384)
    Phase 1/2
    Criterium, Inc.
    Recruiting
    Last update posted :
    07/27/2023
    Initiation :
    04/21/2022
    Primary completion :
    12/01/2024
    Completion :
    01/01/2025
    HER-2 • ER • PGR
    |
    ER positive + PGR positive
    |
    Verzenio (abemaciclib) • Orserdu (elacestrant)
    Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer (ELONA) (NCT05618613)
    Phase 1b
    Context Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    03/28/2023
    Initiation :
    12/02/2022
    Primary completion :
    12/31/2024
    Completion :
    04/30/2026
    HER-2
    |
    Orserdu (elacestrant) • Apristor (onapristone XR)
    Elacestrant in Preoperative Setting, a Window of Opportunity Study (ELIPSE) (NCT04797728)
    Phase 1
    SOLTI Breast Cancer Research Group
    Completed
    Last update posted :
    10/26/2022
    Initiation :
    02/09/2021
    Primary completion :
    02/08/2022
    Completion :
    02/25/2022
    HER-2 • ER • PIK3CA • PTTG1 • RRM2 • CDC20 • CEP55 • UBE2C
    |
    HER-2 negative • PIK3CA mutation
    |
    Orserdu (elacestrant)
    Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer (NCT02650817)
    Phase 1
    Stemline Therapeutics, Inc.
    Completed
    Last update posted :
    08/18/2022
    Initiation :
    04/01/2016
    Primary completion :
    08/30/2018
    Completion :
    10/18/2019
    HER-2 • ER
    |
    ER positive • HER-2 negative • EGFR positive • ER expression
    |
    Orserdu (elacestrant)